Literature DB >> 34585633

Cathelicidin-WA ameliorates diabetic cardiomyopathy by inhibiting the NLRP3 inflammasome.

Meng Peng1, Yuan Liu1, Yawei Xu1, Li Li1, Yan Li1, Haibo Yang1.   

Abstract

Cathelicidin-WA (CWA) is a novel cathelicidin peptide isolated from snakes that has been suggested to exert anti-inflammatory effects. The aim of our study was to investigate whether cathelicidin-WA (CWA) could protect the heart from diabetic cardiomyopathy (DCM). Streptozotocin (STZ) injection was used to establish a mouse model of DCM. CWA peptide (2 mg/kg or 8 mg/kg) was continuously administered to the mice from 10 weeks to 16 weeks after STZ injection. The mice in the DCM group exhibited cardiac dysfunction, while 8 mg/kg CWA ameliorated this cardiac dysfunction. Cardiac fibrosis, inflammation, and oxidative stress as well as cardiomyocyte apoptosis in the DCM mice were decreased by treatment with 8 mg/kg CWA. We isolated neonatal rat cardiomyocytes and stimulated the cells with high glucose to establish an in vitro model of myocyte cell injury. Consistently, CWA inhibited high glucose-induced cell death, inflammation and oxidative stress in the myocytes. Moreover, CWA reduced the formation of the NLR family pyrin domain-containing 3 (NRLP3) inflammasome by regulating thioredoxin-interacting protein expression and p65 activation. NLRP3 overexpression inhibited the beneficial effects of CWA on the heart during DCM and on high glucose-induced myocyte injury. In summary, CWA attenuates cardiac injury and preserves cardiac function during DCM by targeting the NLRP3 pathway.Abbreviations: AAV9: Adeno associated virus; AGE: Advanced Glycation End products; CWA: Cathelicidin-WA; DCM: diabetic cardiomyopathy; Gpx: glutathione peroxidase; HG: high glucose; IL: Interleukin; NLR: Family Pyrin Domain Containing 3 (NRLP3); TXNIP: Thioredoxin interacting protein; LVEF: left ventricular ejection fraction; MDA: Malondialdehyde; MnSOD: manganese superoxide dismutase; NADPH: Nicotinamide adenine dinucleotide phosphate; NAC: N-acetyl-cysteine; NRCMs: Neonatal rat cardiomyocytes; ROS: reactive oxygen species; STZ: Streptozotocin; TNFa: tumor necrosis factor a.

Entities:  

Keywords:  Cathelicidin-WA; NF-κB p65; NLRP3; diabetic cardiomyopathy; thioredoxin interacting protein

Mesh:

Substances:

Year:  2021        PMID: 34585633      PMCID: PMC8794502          DOI: 10.1080/15384101.2021.1981631

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   5.173


  28 in total

1.  Cathelicidin Related Antimicrobial Peptide (CRAMP) Enhances Bone Marrow Cell Retention and Attenuates Cardiac Dysfunction in a Mouse Model of Myocardial Infarction.

Authors:  Yuri M Klyachkin; Amr Idris; Christopher B Rodell; Himi Tripathi; Shaojing Ye; Prabha Nagareddy; Ahmed Asfour; Erhe Gao; Rahul Annabathula; Mariusz Ratajczak; Jason A Burdick; Ahmed Abdel-Latif
Journal:  Stem Cell Rev Rep       Date:  2018-10       Impact factor: 5.739

Review 2.  Sensing and reacting to microbes through the inflammasomes.

Authors:  Luigi Franchi; Raul Muñoz-Planillo; Gabriel Núñez
Journal:  Nat Immunol       Date:  2012-03-19       Impact factor: 25.606

3.  A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes.

Authors:  Riccardo Candido; Josephine M Forbes; Merlin C Thomas; Vicki Thallas; Rachael G Dean; Wendy C Burns; Christos Tikellis; Rebecca H Ritchie; Stephen M Twigg; Mark E Cooper; Louise M Burrell
Journal:  Circ Res       Date:  2003-03-06       Impact factor: 17.367

Review 4.  Implications of Underlying Mechanisms for the Recognition and Management of Diabetic Cardiomyopathy.

Authors:  Thomas H Marwick; Rebecca Ritchie; Jonathan E Shaw; David Kaye
Journal:  J Am Coll Cardiol       Date:  2018-01-23       Impact factor: 24.094

Review 5.  Molecular mechanisms of diabetic cardiomyopathy.

Authors:  Heiko Bugger; E Dale Abel
Journal:  Diabetologia       Date:  2014-01-30       Impact factor: 10.122

Review 6.  Metabolic and Biochemical Stressors in Diabetic Cardiomyopathy.

Authors:  Vasundhara Kain; Ganesh V Halade
Journal:  Front Cardiovasc Med       Date:  2017-05-31

7.  Cathelicidin-related antimicrobial peptide protects against myocardial ischemia/reperfusion injury.

Authors:  Yihua Bei; Li-Long Pan; Qiulian Zhou; Cuimei Zhao; Yuan Xie; Chengfei Wu; Xiangmin Meng; Huanyu Gu; Jiahong Xu; Lei Zhou; Joost P G Sluijter; Saumya Das; Birgitta Agerberth; Jia Sun; Junjie Xiao
Journal:  BMC Med       Date:  2019-02-20       Impact factor: 8.775

8.  Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome.

Authors:  Gonzalo J Martínez; Stacy Robertson; Jennifer Barraclough; Qiong Xia; Ziad Mallat; Christina Bursill; David S Celermajer; Sanjay Patel
Journal:  J Am Heart Assoc       Date:  2015-08-24       Impact factor: 5.501

9.  IRF8 suppresses pathological cardiac remodelling by inhibiting calcineurin signalling.

Authors:  Ding-Sheng Jiang; Xiang Wei; Xiao-Fei Zhang; Yu Liu; Yan Zhang; Ke Chen; Lu Gao; Heng Zhou; Xue-Hai Zhu; Peter P Liu; Wayne Bond Lau; Xinliang Ma; Yunzeng Zou; Xiao-Dong Zhang; Guo-Chang Fan; Hongliang Li
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

10.  High therapeutic efficacy of Cathelicidin-WA against postweaning diarrhea via inhibiting inflammation and enhancing epithelial barrier in the intestine.

Authors:  Hongbo Yi; Lin Zhang; Zhenshun Gan; Haitao Xiong; Caihua Yu; Huahua Du; Yizhen Wang
Journal:  Sci Rep       Date:  2016-05-16       Impact factor: 4.379

View more
  2 in total

1.  Glucose fluctuation promotes cardiomyocyte apoptosis by triggering endoplasmic reticulum (ER) stress signaling pathway in vivo and in vitro.

Authors:  Li-Da Wu; Ying Liu; Feng Li; Jia-Yi Chen; Jie Zhang; Ling-Ling Qian; Ru-Xing Wang
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

2.  Immunomodulatory effects of chicken cathelicidin-2 on a primary hepatic cell co-culture model.

Authors:  Csilla Sebők; Stephanie Walmsley; Patrik Tráj; Máté Mackei; Júlia Vörösházi; Janka Petrilla; László Kovács; Ágnes Kemény; Zsuzsanna Neogrády; Gábor Mátis
Journal:  PLoS One       Date:  2022-10-10       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.